Bristol-Myers Squibb Company Total Liabilities
Bristol-Myers Squibb Company total liabilities. Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has total liabilities worth $65.31 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BMY financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bristol-Myers Squibb Company (1987–2025)
Total liabilities of Bristol-Myers Squibb Company from 1987 to 2025. This chart illustrates how Bristol-Myers Squibb Company's total liabilities have evolved over time, based on quarterly financial data. Explore Bristol-Myers Squibb Company long-term investment intensity to see how much of total assets are deployed in long-term investments.
Bristol-Myers Squibb Company Competitors by Total Liabilities
The table below lists competitors of Bristol-Myers Squibb Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Siemens Energy AG
XETRA:ENR
|
Germany | €52.66 Billion |
|
Capital One Financial Corporation
NYSE:COF
|
USA | $560.04 Billion |
|
Deutsche Telekom AG
F:DTEA
|
Germany | €202.56 Billion |
|
Foxconn Industrial Internet Co Ltd
SHG:601138
|
China | CN¥336.65 Billion |
|
Siemens Energy AG
F:ENR
|
Germany | €48.59 Billion |
|
ABB Ltd
SW:ABBN
|
Switzerland | CHF28.24 Billion |
|
FAST RETAIL.CO.SP.HDR 1
F:FR7H
|
Germany | €1.59 Trillion |
|
SCHNEIDER ELECTR.ADR/1/5
F:SNDB
|
Germany | €38.05 Billion |
Liability Composition Analysis (1987–2025)
This chart breaks down Bristol-Myers Squibb Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bristol-Myers Squibb Company (BMY) total assets.
Liquidity & Leverage Metrics
Bristol-Myers Squibb Company Total Liabilities Ratios Explained
Bristol-Myers Squibb Company total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.75 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bristol-Myers Squibb Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bristol-Myers Squibb Company (1987–2025)
The table below shows the annual total liabilities of Bristol-Myers Squibb Company from 1987 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $71.53 Billion | -6.14% |
| 2024-12-31 | $76.22 Billion | +16.05% |
| 2023-12-31 | $65.67 Billion | -0.04% |
| 2022-12-31 | $65.70 Billion | -10.38% |
| 2021-12-31 | $73.31 Billion | -9.05% |
| 2020-12-31 | $80.60 Billion | +3.01% |
| 2019-12-31 | $78.25 Billion | +275.12% |
| 2018-12-31 | $20.86 Billion | -3.89% |
| 2017-12-31 | $21.70 Billion | +25.02% |
| 2016-12-31 | $17.36 Billion | +0.21% |
| 2015-12-31 | $17.32 Billion | -7.68% |
| 2014-12-31 | $18.77 Billion | -19.65% |
| 2013-12-31 | $23.36 Billion | +4.93% |
| 2012-12-31 | $22.26 Billion | +30.15% |
| 2011-12-31 | $17.10 Billion | +10.79% |
| 2010-12-31 | $15.44 Billion | -4.84% |
| 2009-12-31 | $16.22 Billion | -6.11% |
| 2008-12-31 | $17.28 Billion | +10.69% |
| 2007-12-31 | $15.61 Billion | +0.17% |
| 2006-12-31 | $15.58 Billion | -7.95% |
| 2005-12-31 | $16.93 Billion | -16.32% |
| 2004-12-31 | $20.23 Billion | +14.56% |
| 2003-12-31 | $17.66 Billion | +8.58% |
| 2002-12-31 | $16.27 Billion | -0.34% |
| 2001-12-31 | $16.32 Billion | +94.34% |
| 2000-12-31 | $8.40 Billion | -0.84% |
| 1999-12-31 | $8.47 Billion | -2.61% |
| 1998-12-31 | $8.70 Billion | +12.09% |
| 1997-12-31 | $7.76 Billion | -4.40% |
| 1996-12-31 | $8.12 Billion | +0.10% |
| 1995-12-31 | $8.11 Billion | +12.50% |
| 1994-12-31 | $7.21 Billion | +16.96% |
| 1993-12-31 | $6.16 Billion | +28.78% |
| 1992-12-31 | $4.78 Billion | +32.12% |
| 1991-12-31 | $3.62 Billion | -4.64% |
| 1990-12-31 | $3.80 Billion | +11.25% |
| 1989-12-31 | $3.41 Billion | +2.65% |
| 1988-12-31 | $3.33 Billion | +20.51% |
| 1987-12-31 | $2.76 Billion | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rhe… Read more